Association between glutathione peroxidase-1 (GPX1) Rs1050450 polymorphisms and cancer risk

Glutathione peroxidase (GPX), one of the antioxidant enzymes, exerts a vital role in reducing oxidative damage. GPX1 Pro198Leu (rs1050450) polymorphism has been reported in the development of several cancers, while the results were inconsistent. We thus conducted this meta-analysis to identify the association between GPX1 (rs1050450) polymorphism and cancer risk. 52 eligible publications with 60 case-control studies were included, with 21,296 cancer patients and 30,346 controls. The results in total population suggested there was a significant association between GPX1 (rs1050450) polymorphism and cancer susceptibility in part genetic models (TT vs CT+CC: OR = 1.15, 95% CI = 1.01-1.32, P = 0.042; TT vs CC: OR = 1.15, 95% CI = 1.00-1.31, P = 0.044; T vs C: OR = 1.09, 95% CI = 1.01-1.17, P = 0.02). The stratified analysis by cancer types suggested a positive correlation between GPX1 (rs1050450) polymorphism and the development of bladder cancer (TT+CT vs CC: OR = 1.72, 95% CI = 1.09-2.70, P = 0.019; TT vs CT+CC: OR = 3.56, 95% CI = 1.42-8.94, P = 0.007; TT vs CC: OR = 3.75, 95% CI = 1.41-9.94, P = 0.008; T vs C: OR = 1.941, 95% CI = 1.17-3.22, P = 0.01) as well as head and neck cancer (TT vs CT+CC: OR = 2.19, 95% CI = 1.39-3.46, P = 0.001) and brain cancer (TT+CT vs CC: OR = 1.19, 95% CI = 1.03-1.37, P = 0.018). These results support that GPX1 (rs1050450) polymorphism might be a candidate marker for cancer risk with type-specific effects.